RxDoctor Payments Data

Beverly Chang, MD

Geriatric Psychiatry · Roseville, CANPI 1063716009

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by AbbVie at 33.7% of the total. Reporting peaked in 2023 at $317 and has fallen 70.1% since, to $95 in 2025.

$842in general payments, 2019–2025

Across 15 payments — averaging $56.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$283
  • Axsome Therapeutics, Inc.$205
  • Acadia Pharmaceuticals Inc$132
  • Neurocrine Biosciences, Inc.$123
  • Johnson & Johnson$98

What the payments were for

  • Food & beverage$842100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$842 in reported general payments places this provider in the 80th percentile of 46 geriatric psychiatry providers in California.

See all geriatric psychiatry providers in California

Medicare billing

Part B allowed, 2024
$601,748
Medicare patients
188
Services billed
2,396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate11$54,253
Quetiapine Fumarate129$5,410
Bupropion XlBupropion Hcl128$4,442
Duloxetine Hcl128$3,366
Zolpidem Tartrate82$2,842
Mirtazapine73$2,581
Desvenlafaxine Succinate ErDesvenlafaxine Succinate26$2,103
Lamotrigine93$1,829
Venlafaxine Hcl ErVenlafaxine Hcl97$1,658
Buspirone Hcl86$1,522
Gabapentin88$1,455
Escitalopram Oxalate98$1,272
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine27$1,264
Lorazepam116$1,251
Bupropion Hcl SrBupropion Hcl18$1,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$132$54,25311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 46 geriatric psychiatry providers in California.

Other geriatric psychiatry in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →